Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

12/10/2013 | 08:09am US/Eastern

Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada today announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.

Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.

"We know from our history of engagement that the Canadian bio/pharmaceutical environment is one of the most vibrant in the world," said Robert Urban, Head of the Johnson & Johnson Innovation Center, Boston. "These new collaborations will allow us to potentially advance important new clinical candidates against disease."

"Quebec and Ontario are home to numerous world-class academic and biomedical research enterprises," said Paul Kershaw, Vice President of Medical Affairs, Janssen Inc. in Canada. "These new relationships with NEOMED and MaRS Innovation are an extension of our commitment to Canada's innovative research community."

NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug discovery and development. Partially funded by the Ministère des Finances et de l'Économie du Québec, NEOMED is within the NEOMED Institute, a state-of-the-art R&D facility in the Montréal Technoparc.

MaRS Innovation is the commercialization agent for Ontario's discovery pipeline from 16 leading academic institutions. MaRS Innovation is supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its 16 member institutions.

About Johnson & Johnson Innovation

The Boston Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Corporation. Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early-stage opportunities a one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of those innovations to solve unmet needs in patients. Follow us @jnjinnovation on Twitter. Please visit www.jnjinnovation.com for more information.

About Janssen Inc.

Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, metabolic and chronic diseases and women's health. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. Janssen Inc. in Canada is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssen.ca for more information.

Johnson & Johnson
John Lacey, 781-392-5514
Feinstein Kean Healthcare
Jessica Rowlands, 202-729-4089

© Business Wire 2013
React to this article
Latest news
Date Title
01:32a TEN CATE : Koninklijke Ten Cate NV : Recent trading developments TenCate
01:31a BOUYGUES : Telecom Capital Markets Day
01:31a INNATE PHARMA : Opening of the phase i/ii trial of iph2201 in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia
01:31a INSIDE SECURE : and EZchip Partner to Provide Best of Breed Internet Data Security for Cloud Computing, Digital Video, and Advanced Networking Applications
01:31a ADOCIA : and Lilly Initiate a Phase 1b Study Evaluating Ultra-Rapid BioChaperone Lispro in Patients with Type 1 Diabetes Using Insulin Pump Therapy
01:29a AUDI : Local car owners are safe - Volkswagen
01:29a MANCHESTER UNITED : Klopp is at the top of Reds list for new boss
01:29a EMPIRE ENERGY : Change of Director's Interest Notice x 2
01:29a EMPIRE ENERGY : Notice of Adjustment to Option Exercise Prices
01:25aDJU.S. Probes Alleged U.N. Bribe Scheme
Latest news
Hot News 
APR ENERGY : Reveals it is in takeover talks
DEERE MPANY : Whirlpool reach labor deals
Peltz Asks Little of GE, for Now
SANDRIDGE ENERGY : to buy west Texas gathering system
LGI Homes, Inc. Reports September and Third Quarter 2015 Home Closings
Most Read News
10/05 PSA PHILIPPINE STATISTICS AUTHORITY : Producer Price Survey : August 2015
10/05 UNIVERSITY OF ADELAIDE : Tequila plant shows promise for biofuel
10/05 British Airways' last flight out of Uganda
10/05 QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch
10/05 Allocadia's Twin Co-Founders Named to Forty Under 40 List by BIV
Most recommended articles
01:25aDJU.S. Probes Alleged U.N. Bribe Scheme
01:09aDJASIA MARKETS : Japan Leads Asian Shares Higher On Bets BOJ Will Loosen Up
01:05aDJAustralia Trade Deficit Widens
01:05aDJJapan Leads Asian Shares Higher--2nd Update
01:00a Euro, Yen May Rise if Fed Comments Rekindle 2015 Rate Hike Bets